Stem Cell Clinic

Animal Rehabilitation and Wellness Center Gives Castle Rock Golden Retriever a Second Chance to Enjoy Life with Stem …

Poway, CA (PRWEB) September 17, 2013

Over the course of last year, Deuce, a five year old Golden Retriever, was being treated by Dr. Cheryl Adams at Animal Rehabilitation and Wellness Center of Castle Pines for pain that had became so severe that he would require pain medication to get around on most days. Dr. Adams turned to stem cell therapy in April to battle Deuces pain, and just five months since Deuces stem cell therapy his owner, Laura Preston, is happy to report that He has very few sore days, and I have not seen him be stiff or lame in a few months.

Deuce was only four when he started to show signs of discomfort in his back legs. As a Golden Retriever, Deuce can be expected to live an average of 11 active and energetic years, but as a youngster he collided with another dog playing on the beach when he lived in warm San Diego. There were no immediate effects from the accident, but his first winter in cold Colorado brought some issues to owner, Lauras attention.

Deuce was having difficulty getting up from a lying position, walking around the house, or just standing for any length of time. Never mind the fun activities he used to enjoy like long walks in his beautiful home of Castle Rock, Colorado, or enjoying a swim. Dr. Adams and Deuces owners refused to allow him to live with such a decreased quality of life at the young age of five.

Dr. Adams collected a small portion of Deuces fat, which naturally has stem cells in it, and sent it to Vet-Stems lab in San Diego, California. In 48 hours Dr. Adams received a concentrated number of Deuces own stem cells for injection into his hocks. Dr. Adams and Deuces owners hoped stem cells would improve Deuces quality of life by decreasing his pain enough to allow him to stop daily medication and enjoy the activities he used to love so much.

The first few weeks after stem cells he was like a one year old puppy, Laura described, Running and jumping around with no issues. Slowly increasing Deuces movement over time, he was able to return to his full activity level and by three months he had only one noticeably sore day a week. He can run and swim fine, Laura states, All in all he has great improvement!

Deuces veterinarian, Dr. Adams, has been a long-time supporter of stem cell therapy and regenerative medicine in animals. In 2005, Dr. Adams began working with Vet-Stem as a clinical study investigator, and became one of the first credentialed Veterinarians for stem cell treatment. She was involved in the initial small animal clinical studies utilizing autologous, fat derived, stem and regenerative cells to treat orthopedic conditions. She is a published author who in 2007 received an award for Regenerative Stem Cell use in companion animals.

The Animal Rehabilitation and Wellness Center of Castle Pines is proud to be a designated Center of Excellence for Vet-Stem Regenerative Veterinary Medicine, and for their breakthrough work in stem cell therapy. ARWC continues to help with the investigation of the use of stem cell therapy for other diseases such as inflammatory bowel disease (IBS), select neurologic diseases, kidney disease, some liver disease, and atopy (skin allergies), with the goal to achieve optimal wellness and health in companion animals of all ages. ARWC is a referral center committed to helping companion pets recover from illness, injury and surgery.

About Vet-Stem, Inc. Vet-Stem, Inc. was formed in 2002 to bring regenerative medicine to the veterinary profession. The privately held company is working to develop therapies in veterinary medicine that apply regenerative technologies while utilizing the natural healing properties inherent in all animals. As the first company in the United States to provide an adipose-derived stem cell service to veterinarians for their patients, Vet-Stem, Inc. pioneered the use of regenerative stem cells in veterinary medicine. The company holds exclusive licenses to over 50 patents including world-wide veterinary rights for use of adipose derived stem cells. In the last decade over 10,000 animals have been treated using Vet-Stem, Inc.s services, and Vet-Stem is actively investigating stem cell therapy for immune-mediated and inflammatory disease, as well as organ disease and failure. For more on Vet-Stem, Inc. and Veterinary Regenerative Medicine, visit http://www.vet-stem.com or call 858-748-2004.

See the original post here:
Animal Rehabilitation and Wellness Center Gives Castle Rock Golden Retriever a Second Chance to Enjoy Life with Stem ...

New York Genome Center announces the New York Stem Cell Foundation as an Associate Member

Public release date: 17-Sep-2013 [ | E-mail | Share ]

Contact: David McKeon dmckeon@nyscf.org 212-365-7440 New York Stem Cell Foundation

New York, NY (September 17, 2013) The New York Genome Center (NYGC) announced today that The New York Stem Cell Foundation (NYSCF) has become an Associate Member, joining NYGC's growing consortium of 16 research and clinical institutions, all working together in new ways to utilize genomic data for better detection, treatment, and prevention of disease.

"Biologists at the NYSCF working with the genomic scientists at NYGC will help address some of the critical roadblocks in stem cell research," said Dr. Robert B. Darnell, President and Scientific Director of NYGC. "Modern genomics has the potential to provide vital missing information to help us learn how to harness stem cells for use in clinical medicine. We've developed techniques and ideas here at NYGC that will greatly synergize with the beautiful and pioneering work ongoing at the NYSCF."

Stem cell biology and genomic analysis are both critical to the advancement of precision medicine. The collaboration between the Genome Center and NYSCF will merge cutting-edge capabilities in human biology with genomic research, creating an optimal environment for translating research into a better standard of care for patients.

"We are excited to work with NYGC as we continue to accelerate cures for the major diseases of our time. This will enable collaboration within the growing biotechnology community in New York," said Susan L. Solomon, CEO of The New York Stem Cell Foundation. "NYSCF has a number of current projects in which additional genomic analysis may play a critical role in better understanding disease susceptibility and risk factors. We hope to work with NYGC to integrate their genomic analysis into our research."

The New York Genome Center provides an "Integrated Genomics Solution", which includes (1) scientific consultation, (2) next-generation sequencing services for exomes, whole genomes, and RNA, (3) bioinformatic analysis of sequencing results using a high performance computing environment, and (4) data storage so that researchers and clinicians can readily access these results.

As an Associate Member, NYSCF will have priority access to these services. NYSCF will also become a member of the NYGC's Scientific and Clinical Steering Committee (SCSC), which provides guidance on research direction and oversees research collaborations and related funding.

NYSCF employs 45 full-time scientists and engineers in its laboratory who are engaged in the most advanced stem cell research and technology development, including creating NYSCF's Global Stem Cell Array, an automated technology platform that for the first time makes it possible to create identical stem cell lines from a large number of patients in a massively parallel process. This is a revolutionary tool that takes the vast amount of information we have learned from sequencing the human genome and puts it into a biological context to accelerate the development of safe and effective medicine. This robotic system creates induced pluripotent stem (iPS) cell lines and cell derivatives in a standardized manner from genetically diverse patients and patients with disease. This program will create an array of stem cell lines representing the full range of human genetics and the diversity of the world's population.

"This collaboration will expand our resources to analyze our stem cell samples at the genetic level, as we continue to bring the latest discoveries in genome science to our work to understand, prevent, and eventually cure diseases like diabetes, Alzheimer's, and multiple sclerosis among many others," said Scott Noggle, Director of the NYSCF Laboratory and the Charles Evans Senior Research Fellow for Alzheimer's Disease.

Link:
New York Genome Center announces the New York Stem Cell Foundation as an Associate Member

Southern California Regenerative Medicine Clinics Now Offering Stem Cell Therapy for Degenerative Disc Disease and …

Orange, CA (PRWEB) September 17, 2013

The top regenerative medicine clinic in Southern California, TeleHealth, is now offering stem cell therapy for back pain due to degenerative disc disease. The treatment has the potential to repair and regenerate damaged spinal discs and is performed as an outpatient procedure. For more information and scheduling, call (888) 828-4575.

One of the most troublesome spinal conditions to treat has been degenerative disc disease. Normally, a spinal disc contains 80% water. However, as it degenerates that percentage decreases and the discs are not great at regenerating themselves. This degeneration may unfortunately happen at a young age due to genetics or post traumatic deterioration.

TeleHealth, the leading stem cell therapy clinic in California, is now offering regenerative medicine treatments for degenerative disc disease. This includes either platelet rich plasma therapy (PRP), bone marrow derived stem cell injections, fat derived stem cell injections or a combination of therapies.

The treatments are on the cutting edge of medicine and have brought home to millions of individuals suffering from degenerative arthritis, disc disease and soft tissue injuries. TeleHealth also provides stem cell injections for osteoarthritis, rotator cuff tendonitis, achilles tendonitis, tennis elbow, ligament sprains and new indications such as hair loss and breast reconstruction after cancer.

The essential problem is that the metabolism of the degenerative disc is too slow and not able to heal itself. Stem cell treatments bring in vital reparative cells to the area along with growth factors to spur healing. The stem cell treatments for degenerative disc disease are not covered by insurance, however, most other treatments are at TeleHealth.

The treatments are all outpatient and offered by Board Certified doctors. For more information and scheduling of stem cell treatments for disc disease, call (888) 828-4575.

Follow this link:
Southern California Regenerative Medicine Clinics Now Offering Stem Cell Therapy for Degenerative Disc Disease and ...

Mesenchymal stem cell transplantation may heal a mother's childbirth injury

Public release date: 17-Sep-2013 [ | E-mail | Share ]

Contact: Robert Miranda cogcomm@aol.com Cell Transplantation Center of Excellence for Aging and Brain Repair

Putnam Valley, NY. (Sept. 17 2013) Vaginal delivery presents the possibility of injury for mothers that can lead to "stress urinary incontinence" (SUI), a condition affecting from four to 35 percent of women who have had babies via vaginal delivery. Many current treatments, such as physiotherapy and surgery, are not very effective.

Seeking better methods to alleviate SUI, researchers carried out a study in which female laboratory rats modeled with simulated childbirth injuries received injections of mesenchymal stem cells (MSCs; multipotent cells found in connective tissues that can differentiate into a variety of cell types including: bone, cartilage and fat cells) to see if the cells would home to and help to repair the damaged pelvic organs.

The study appears as an early e-publication for the journal Cell Transplantation, and is now freely available on-line at http://www.ingentaconnect.com/content/cog/ct/pre-prints/content-cog_09636897_ct0957dissaranan.

"Stem cell-based therapy has recently gained attention as a promising treatment for SUI," said study co-author Dr. Margot S. Damaser of the Cleveland Clinic's Department of Biomedical Engineering. "Stem cell therapies may be more feasible and less invasive than current therapies."

The current study extended the results of the researcher's previous studies by demonstrating that the transplanted MSCs homed to the animals' spleens. This suggested that the transplanted cells could have a beneficial impact when they released trophic factors, agents that stimulate differentiation and survival of cells and then engrafted into the smooth muscle of the urethra and vagina, as demonstrated previously in prior studies.

"Our results suggest a potential therapy for postpartum SUI," said Dr. Damaser.

The group of female rats that received simulated childbirth injury (vaginal distension) and MSCs showed homing of the MSCs to the urethra and vagina, facilitating the recovery of continence.

The researchers noted that other kinds of stem cells from different sources have been used in other studies aimed at treating SUI via stem cell transplantation. Autologous (self-donated) muscle-derived stem cells have demonstrated therapeutic potential for SUI in animal models and in clinical trials. Adipose (fat)-derived stem cells have also been used to improve urethral function after simulated childbirth injury in rats.

The rest is here:
Mesenchymal stem cell transplantation may heal a mother's childbirth injury

Stem Cell Therapeutics Adopts Shareholder Rights Plan

TORONTO, ONTARIO--(Marketwired - Sep 17, 2013) - Stem Cell Therapeutics Corp. (TSX VENTURE:SSS)(SCTPF), a biopharmaceutical company developing cancer stem cell-related therapeutics, today announces that it has adopted a shareholder rights plan (the "Plan") effective September 16, 2013. The Company will be seeking shareholder approval of the Plan at its next annual general and special meeting of shareholders.

The Plan is designed to ensure the fair and equal treatment of shareholders in connection with any take-over bid for outstanding common shares of the Company. The Plan is not intended to prevent or deter take-over bids that offer fair treatment and value to shareholders, but is designed to encourage offers that represent fair value to all shareholders. The Plan seeks to provide shareholders with adequate time to properly assess a take-over bid without undue pressure. It also provides the Board of Directors with adequate time to fully assess an unsolicited take-over bid, to allow competing bids to emerge, and, if applicable, to explore other alternatives to the take-over bid to maximize shareholder value.

Under the terms of the Plan, one right will be issued by the Company for each outstanding Stem Cell Therapeutics ("SCT") common share at the close of business on September 16, 2013, and for each SCT common share issued in the future (subject to the terms of the Plan). The rights issued under the Plan become exercisable only if a person acquires or announces its intention to acquire 20% or more of the common shares of the Company without complying with the "Permitted Bid" provisions of the Plan or without the approval of SCT's Board of Directors.

Permitted Bids must be made to all holders of SCT common shares by way of a take-over bid circular prepared in compliance with applicable securities laws and, among other things, must be open for acceptance for a minimum of 60 days. If at the end of 60 days at least 50% of the outstanding common shares other than those owned by the offeror and certain related parties have been tendered and not withdrawn, the bidder may take-up and pay for the shares but must extend the bid for a further 10 days to allow other shareholders to tender to the bid.

If a take-over bid does not meet the Permitted Bid requirements of the Plan, the rights will entitle shareholders, excluding the shareholder or shareholders making the take-over bid, to purchase additional common shares of the Company at a substantial discount to the market price of the common shares at that time.

The Company is not adopting a Plan in response to any proposal to acquire control of the Company. The Plan is similar to plans adopted by other Canadian companies and ratified by their shareholders.

Although effective as of September 16, 2013, the Plan will be presented for ratification by the Company's shareholders at the next annual general and special meeting. If ratified by the shareholders, the Plan will have an initial term of 3 years.

About Stem Cell Therapeutics:

Stem Cell Therapeutics Corp. is a biopharmaceutical company advancing cancer stem cell discoveries into novel and innovative cancer therapies. Building on over half a century of leading and groundbreaking Canadian stem cell research, the company is supported by established links to a group of Toronto academic research institutes and cancer treatment centers, representing one of the world's most acclaimed cancer research hubs. The Company has two premier preclinical programs, SIRPaFc and a CD200 monoclonal antibody ("mAb"), which target two key immunoregulatory pathways that tumor cells exploit to evade the host immune system. SIRPaFc is an antibody-like fusion protein that blocks the activity of CD47, a molecule that is upregulated on cancer stem cells in AML and several other tumors. The CD200 mAb is a fully human monoclonal antibody that blocks the activity of CD200, an immunosuppressive molecule that is overexpressed by many hematopoietic and solid tumors. SCT's clinical stage programs include the recently in-licensed program focused on the structure of tigecycline, which is currently being evaluated in a multi-centre Phase I study in patients with acute myeloid leukemia ("AML"), as well as TTI-1612, a non-oncology asset that recently completed dosing in a 28-patient Phase I trial in interstitial cystitis ("IC") patients. For more information, visit http://www.stemcellthera.com.

Caution Regarding Forward-Looking Information:

Original post:
Stem Cell Therapeutics Adopts Shareholder Rights Plan